The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
5-[1-(2,4-difluorophenyl)pyrazolo[3,4-b]pyridin-4-yl]pyrimidin-4-amine ID: ALA5282485
Max Phase: Preclinical
Molecular Formula: C16H10F2N6
Molecular Weight: 324.29
Associated Items:
Names and Identifiers Canonical SMILES: Nc1ncncc1-c1ccnc2c1cnn2-c1ccc(F)cc1F
Standard InChI: InChI=1S/C16H10F2N6/c17-9-1-2-14(13(18)5-9)24-16-12(7-23-24)10(3-4-21-16)11-6-20-8-22-15(11)19/h1-8H,(H2,19,20,22)
Standard InChI Key: GDCKYRZIPLGNHK-UHFFFAOYSA-N
Molfile:
RDKit 2D
24 27 0 0 0 0 0 0 0 0999 V2000
-1.5420 1.0791 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.5435 0.2541 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.2587 -0.1569 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.8298 -0.1596 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.1145 0.2515 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.1131 1.0765 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.8267 1.4903 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.5029 -0.3208 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.1709 -1.0546 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.6529 -0.9607 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.3000 -0.1072 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.5138 0.6898 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.3088 0.9020 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.8925 0.3183 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.6815 -0.4751 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.8861 -0.6933 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.6896 0.5319 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
-2.2603 -0.9821 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.9757 -1.3935 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-3.6896 -0.9795 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.6881 -0.1542 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-2.9727 0.2569 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.9727 1.0821 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.6725 -1.4903 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
2 4 1 0
4 5 2 0
5 6 1 0
6 7 2 0
7 1 1 0
5 8 1 0
8 9 1 0
10 9 2 0
4 10 1 0
8 11 1 0
12 11 2 0
13 12 1 0
14 13 2 0
15 14 1 0
16 15 2 0
11 16 1 0
14 17 1 0
18 3 2 0
19 18 1 0
20 19 2 0
21 20 1 0
22 21 2 0
3 22 1 0
22 23 1 0
16 24 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Topical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 324.29Molecular Weight (Monoisotopic): 324.0935AlogP: 2.74#Rotatable Bonds: 2Polar Surface Area: 82.51Molecular Species: NEUTRALHBA: 6HBD: 1#RO5 Violations: ┄HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski): ┄CX Acidic pKa: ┄CX Basic pKa: 5.17CX LogP: 2.00CX LogD: 2.00Aromatic Rings: 4Heavy Atoms: 24QED Weighted: 0.61Np Likeness Score: -1.68
References 1. Padmakar Darne C, Velaparthi U, Saulnier M, Frennesson D, Liu P, Huang A, Tokarski J, Fura A, Spires T, Newitt J, Spires VM, Obermeier MT, Elzinga PA, Gottardis MM, Jayaraman L, Vite GD, Balog A.. (2022) The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer., 75 [PMID:36031020 ] [10.1016/j.bmcl.2022.128951 ]